DE68915675T2 - Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen. - Google Patents

Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.

Info

Publication number
DE68915675T2
DE68915675T2 DE68915675T DE68915675T DE68915675T2 DE 68915675 T2 DE68915675 T2 DE 68915675T2 DE 68915675 T DE68915675 T DE 68915675T DE 68915675 T DE68915675 T DE 68915675T DE 68915675 T2 DE68915675 T2 DE 68915675T2
Authority
DE
Germany
Prior art keywords
vitamin
proteins
purification
dependent proteins
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68915675T
Other languages
English (en)
Other versions
DE68915675T3 (de
DE68915675D1 (de
Inventor
Sau-Chi Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26943089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68915675(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE68915675D1 publication Critical patent/DE68915675D1/de
Publication of DE68915675T2 publication Critical patent/DE68915675T2/de
Publication of DE68915675T3 publication Critical patent/DE68915675T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/647Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478Aspartic endopeptidases (3.4.23)
    • C12N9/6481Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE68915675T 1988-10-04 1989-10-02 Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen. Expired - Lifetime DE68915675T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327988A 1988-10-04 1988-10-04
US07/393,281 US4981952A (en) 1988-10-04 1989-08-16 Method for the purification of vitamin K-dependent proteins

Publications (3)

Publication Number Publication Date
DE68915675D1 DE68915675D1 (de) 1994-07-07
DE68915675T2 true DE68915675T2 (de) 1994-10-20
DE68915675T3 DE68915675T3 (de) 2002-08-14

Family

ID=26943089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68915675T Expired - Lifetime DE68915675T3 (de) 1988-10-04 1989-10-02 Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.

Country Status (13)

Country Link
US (1) US4981952A (de)
EP (1) EP0363126B2 (de)
JP (1) JP2848461B2 (de)
KR (1) KR0139209B1 (de)
AT (1) ATE106406T1 (de)
AU (1) AU635222B2 (de)
CA (1) CA1314011C (de)
DE (1) DE68915675T3 (de)
DK (1) DK176090B1 (de)
ES (1) ES2054019T5 (de)
HU (1) HU204538B (de)
IE (1) IE63765B1 (de)
IL (1) IL91822A (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE3833936C1 (de) * 1988-10-05 1989-09-21 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
DE3911629A1 (de) * 1989-04-10 1990-10-11 Behringwerke Ag Verfahren zur abtrennung von toxinen aus proteinloesungen
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
CA2105282C (en) 1991-03-01 2002-09-24 Centeon L.L.C. Preparation of factor ix
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US5843731A (en) * 1996-09-05 1998-12-01 Asahi Kogaku Kogyo Kabushiki Kaisha Method for purifying plasmid DNA on calcium phosphate compound
US5910584A (en) * 1996-09-05 1999-06-08 Asahi Kogaku Kogyo Kabushiki Kaisha Method for isolating plasmid DNA
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1557463A1 (de) * 1997-04-28 2005-07-27 Eli Lilly & Company Verbesserte Methoden zur Verarbeitung von aktiviertem Protein C
JP2002502421A (ja) * 1997-06-05 2002-01-22 イーライ・リリー・アンド・カンパニー 血栓障害の処置方法
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
BR9914735A (pt) 1998-10-22 2001-07-03 Lilly Co Eli Processo para tratamento de sépsia
CN1326355A (zh) 1998-11-13 2001-12-12 伊莱利利公司 治疗肝素诱导的血小板减少症的方法
CA2351470A1 (en) 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
EP1133314B1 (de) 1998-11-23 2003-02-19 Eli Lilly And Company Protein c zur behandlung von sichelzellanämie und thalassämie
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002008249A1 (fr) * 2000-07-21 2002-01-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Procede de purification de la proteine de liaison a l'ion calcium
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
JP4628618B2 (ja) * 2001-09-26 2011-02-09 富士フイルム株式会社 撮像光学系
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1651252B1 (de) * 2003-07-08 2014-11-26 The Scripps Research Institute Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
WO2006067230A1 (en) 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
PT1841863E (pt) * 2005-01-14 2010-10-25 Bayer Healthcare Llc Método para a purificação de factor vii
JP2008543925A (ja) * 2005-06-24 2008-12-04 ダラグレキュル・アンパルトセルスカブ 呼吸器系に影響を及ぼす炎症状態における組織因子系凝固インヒビターの気道投与
WO2007071767A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk Health Care Ag Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography (rpc)
DK2004683T3 (en) * 2006-03-24 2016-08-22 Biogen Hemophilia Inc PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
EP2078074A4 (de) * 2006-10-31 2011-09-28 Scripps Research Inst Dosierplan für aktiviertes protein-c und varianten mit verminderter gerinnungshemmender wirkung
DK2125866T3 (da) * 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
US20100081187A1 (en) 2007-04-26 2010-04-01 Griffith Michael J Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
KR101821143B1 (ko) * 2008-12-02 2018-01-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드 정제
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
EP2199387A1 (de) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
EP2494040B1 (de) 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Verfahren zur herstellung rekombinanter vitamin-k-abhängiger proteine
US9896677B2 (en) 2010-01-18 2018-02-20 Novo Nordisk Health Care Ag Purification of blood coagulation factors
KR101780518B1 (ko) * 2010-04-29 2017-09-21 박스알타 인코퍼레이티드 음이온 교환 수지상에서의 2가 양이온 결합 단백질의 정제 방법
CN103547589A (zh) 2011-03-29 2014-01-29 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
KR20140057348A (ko) * 2011-09-06 2014-05-12 메디뮨 엘엘씨 응고 인자를 처리하는 방법
US10378004B2 (en) 2011-10-14 2019-08-13 Baxalta GmbH Protein purification by anion exchange chromatography
US9701710B2 (en) 2011-10-14 2017-07-11 Baxalta Incorporated Protein purification by anion exchange chromatography
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
HUE037677T2 (hu) 2013-03-15 2018-09-28 Baxalta Inc K-vitamin függõ fehérjék anioncserélõ kromatográfiás tisztítására szolgáló eljárás
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
WO2017118910A1 (en) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512992A (en) * 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4766224A (en) * 1985-08-19 1988-08-23 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4677196A (en) * 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DE3615558A1 (de) * 1986-05-09 1987-11-12 Behringwerke Ag Verfahren zur herstellung eines faktor v-konzentrats

Also Published As

Publication number Publication date
DK485589D0 (da) 1989-10-03
EP0363126A2 (de) 1990-04-11
DE68915675T3 (de) 2002-08-14
DE68915675D1 (de) 1994-07-07
ES2054019T3 (es) 1994-08-01
DK485589A (da) 1990-04-05
ES2054019T5 (es) 2002-10-16
CA1314011C (en) 1993-03-02
HU204538B (en) 1992-01-28
HUT53373A (en) 1990-10-28
ATE106406T1 (de) 1994-06-15
IE63765B1 (en) 1995-06-14
KR0139209B1 (ko) 1998-04-30
EP0363126B2 (de) 2002-03-06
KR900006511A (ko) 1990-05-08
JPH02200180A (ja) 1990-08-08
IL91822A0 (en) 1990-06-10
IE893159L (en) 1990-04-04
DK176090B1 (da) 2006-05-22
EP0363126A3 (de) 1991-09-11
IL91822A (en) 2001-06-14
JP2848461B2 (ja) 1999-01-20
AU635222B2 (en) 1993-03-18
AU4251989A (en) 1990-04-12
EP0363126B1 (de) 1994-06-01
US4981952A (en) 1991-01-01

Similar Documents

Publication Publication Date Title
DE68915675T3 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
ATE370961T1 (de) Reinigung von antikörpern durch ionenaustauschchromatographie
ES8100502A1 (es) Un procedimiento para purificar proteinas con pesos moleculares superiores a 12.000,en particular interferon
DK0460426T3 (da) Fremgangsmåde til proteinrensning
ATE154033T1 (de) Verfahren zur reinigung von proteinen
FI103974B1 (fi) Menetelmä proteiinin puhdistamiseksi
KR900003207A (ko) 트롬빈 결합성 물질 및 이의 제조방법
BR8108074A (pt) Sequencia de dna,plasmidio recombinante,ligadores de dna,cultura bacterial e processo para produzir taumatina
ATE20540T1 (de) Vollsynthetisches zellkulturmedium.
ATE166062T1 (de) Verfahren zur reinigung des big-endothelin proteins
ATE135402T1 (de) Reinigung von erwinia-l-asparaginase
DE3788170D1 (de) Methode zur Reinigung und Isolierung von zwei ionischen Formen von Somatomedin.
ATE76082T1 (de) Reinigungsmethode fuer antikoerper.
ATE33842T1 (de) Immuninterferon und verfahren zu seiner reinigung.
Ruff et al. Glycoprotein Proteinase in Agkistrodon bilineatus Venom
KR880001805A (ko) 조 임파구 인터페론의 정제방법
KR920012426A (ko) 인간 표피 성장 인자의 정제방법

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings